Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02335242 · ClinicalTrials.gov registry record · Phase 2
Sildenafil for the Treatment of Lymphatic Malformations
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02335242: Completed Phase 2 study, sponsored by Stanford University.
NCT02335242 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02335242, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
A Phase 2 study to evaluate safety and efficacy of sildenafil taken orally to improve or resolve lymphatic malformations in children. Subjects may receive either placebo or treatment in an oral dosage with an open label extension for subjects who received placebo. The study treatment assignment will be randomized in a double blind fashion. MRI examination will evaluate change in lesion volume due to treatment. Other safety and efficacy measures will be taken through the 32-week study duration. Funding Source - FDA OOPD
Interventions
- DRUG Sildenafil 20 mg tablets
- OTHER Placebo tablets (resembling Revatio)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-05-23 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02335242
The ClinicalTrials.gov registry entry for NCT02335242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sildenafil 20 mg tablets is the first listed.
NCT02335242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02335242 about?
NCT02335242 is a clinical study titled "Sildenafil for the Treatment of Lymphatic Malformations". A Phase 2 study to evaluate safety and efficacy of sildenafil taken orally to improve or resolve lymphatic malformations in children. Subjects may receive either placebo or treatment in an oral dosage with an open label extension for subjects who received placebo. The study treatment assignment will...
What is the current status of trial NCT02335242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-05-23. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT02335242?
The interventions under investigation include: Sildenafil 20 mg tablets (DRUG), Placebo tablets (resembling Revatio) (OTHER).
Who is sponsoring clinical trial NCT02335242?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.